### LICENCE AGREEMENT

### **BETWEEN**

- (1) **HEALTHCARE QUALITY IMPROVEMENT PARTNERSHIP** (company number 06498947) whose registered office is at 70 Wimpole Street, London W1G 8AX (the "AUTHORITY"); and
- (2) ("the LICENSEE")

### Recital:

The Authority has agreed to grant the Licensee a limited non-exclusive royalty-free revocable licence to use the Audit Tool upon the terms and conditions of this Agreement.

Operative provisions:

### 1 DEFINITIONS AND INTERPRETATION

1.1 In this Agreement the following words shall have the following meanings:-

	_
"Audit Tool"	means the data collection tool known as the Audit Tool developed by the National Audit of Schizophrenia (NAS) in relation to the NAS project under a contract with the Authority as set out in Schedule 1, and shall be interpreted as including any Updated Audit Tool;
"Intellectual Property Rights"	means patents, trademarks, copyrights, rights to extract information from a database, design rights and all rights or forms of protection of a similar nature or having equivalent or the similar effect to any of them which may subsist anywhere in the world, whether or not any of them are registered and including applications for registration of any of them and including Know How;
"Know How"	means all technical and other information which is not in the public domain, including but not limited to information comprising or relating to concepts, discoveries, data, designs, formulae, ideas, inventions, methods, models, procedures, designs for experiments and tests and results of experimentation and testing, processes, specifications and techniques, laboratory records, clinical data, manufacturing data and information contained in submissions to regulatory authorities;
"Loss"	means all costs, claims, liabilities and expenses (including reasonable legal expenses);
"Territory"	means England and Wales;
"Updated Audit Tool"	means any modified, improved or corrected version of the Audit Tool as created or developed by the Licensee and approved by the Authority in accordance with Clause 4;
"Use"	means to use the Audit Tool for non-commercial purposes for the carrying out of the Initial Health Assessment and the Review Health Assessments for Looked After Children and children in

care;

- 1.2 In this Agreement (except where the context otherwise requires):
  - 1.2.1 use of the singular includes the plural (and *vice versa*) and use of any gender includes the other genders;
  - 1.2.2 a reference to a party is to a party to this Agreement and shall include that party's personal representatives, successors or permitted assignees;
  - 1.2.3 a reference to persons includes natural persons, firms, partnerships, bodies corporate and corporations, and associations, organisations, governments, states, foundations, trusts and other unincorporated bodies (in each case whether or not having separate legal personality and irrespective of their jurisdiction of origin, incorporation or residence); and
  - 1.2.4 a reference to a Clause or Schedule is to the relevant clause of or schedule to this Agreement.
  - 1.2.5 any reference to a statute, order, regulation or other similar instrument shall be construed as a reference to the statute, order, regulation or instrument together with all rules and regulations made under it as from time to time amended, consolidated or re-enacted by any subsequent statute, order, regulation or instrument;
  - 1.2.6 general words are not to be given a restrictive meaning because they are followed by particular examples, and any words introduced by the terms "including", "include", "in particular" or any similar expression will be construed as illustrative and the words following any of those terms will not limit the sense of the words preceding those terms; and
  - 1.2.7 headings to clauses are for the purpose of information and identification only and shall not be construed as forming part of this Agreement.
- 1.3 The Schedules form an integral part of this Agreement and have effect as if set out in full in the body of this Agreement. A reference to this Agreement includes the Schedules.

### 2 GRANT OF LICENCE

2.1 The Authority hereby grants to the Licensee a limited non-exclusive royalty-free revocable licence to Use the Audit Tool within the Territory upon the terms and conditions of this Agreement.

### 3 DURATION OF AGREEMENT

3.1 This licence granted by Clause 2.1 shall commence on the date of this Agreement and shall continue for a period of three years or terminated in accordance with the provisions of Clause 6 below.

### 4 VARIATIONS TO THE AUDIT TOOL

- 4.1 The Licensee may not make modifications, improvements or corrections to the Audit Tool other than with the express written permission of the Authority.
- 4.2 If approved by the Authority any such modifications, improvements or corrections that may be incorporated into the Audit Tool to create an Updated Audit Tool.

### 5 INTELLECTUAL PROPERTY

- 5.1 The Audit Tool is the confidential information of the Authority and all Intellectual Property Rights in the Audit Tool are the exclusive property of the Authority.
- 5.2 The Authority shall retain title and all ownership rights in the Audit Tool. This Agreement does not grant the Licensee any Intellectual Property Rights in the Audit Tool and the original and all copies of the Audit Tool shall remain the property of the Authority.
- 5.3 The Licensee agrees that any Intellectual Property Rights it may have in any Updated Audit Tools will belong to and vest in the Authority. The Licensee shall do any acts requested by the Authority to ensure such rights vest legally in the Authority.
- 5.4 The Licensee confirms that it will make clear on any relevant documentation that the Authority is the owner of the Audit Tool.
- 5.5 The Authority asserts its moral rights under the Copyright, Designs & Patents Act 1988 to be identified as the author of the Audit Tool and its right not to have the Audit Tool subjected to derogatory treatment.
- 5.6 The Licensee shall notify the Authority immediately if the Licensee becomes aware of any unauthorised use of the whole or any part of the Audit Tool by any third party.
- 5.7 The Licensee shall take all such other steps as shall from time to time be necessary to protect the confidential information and Intellectual Property Rights of the Authority in the Audit Tool.
- 5.8 The Licensee shall inform all relevant employees, agents and sub-contractors that the Audit Tool constitutes confidential information of the Authority and that all Intellectual Property Rights therein are the property of the Authority and the Licensee shall take all such steps as shall be necessary to ensure compliance by its employees, agents and sub-contractors with the provisions of this Clause 5.

### 6 TERMINATION

- 6.1 This Agreement may be terminated:
  - 6.1.1 by the Authority upon giving not less than 28 days' notice to the Licensee;
  - 6.1.2 forthwith by either party if the other commits any material breach of any term of this Agreement and which (in the case of a breach capable of being remedied) shall not have been remedied within 14 days of a written request to remedy the same;
  - 6.1.3 forthwith by either party if the other shall convene a meeting of its creditors or if a proposal shall be made for a voluntary arrangement within Part I of the Insolvency Act 1986 or a proposal for any other composition scheme or arrangement with (or assignment for the benefit of) its creditors or if the other shall be unable to pay its debts within the meaning of section 123 of the Insolvency Act 1986 or if a trustee receiver administrative receiver or similar officer is appointed in respect of all or any part of the business or assets of the other or if a petition is presented or a meeting is convened for the purpose of considering a resolution or other steps are taken for the winding up of the other or for the making of an administration order (otherwise than for the purpose of an amalgamation or reconstruction) or similar steps are taken in a jurisdiction other than England or Wales.
- 6.2 Subject to Clause 6.3 below within 7 days of the termination of this Agreement (howsoever and by whomsoever occasioned) the Licensee shall at the Authority's sole option either return or shall destroy all copies of the Audit Tool in its possession or control and a duly authorised officer of the Licensee shall certify in writing to the Authority that the Licensee has complied with its obligation as aforesaid.

6.3 Notwithstanding the provisions of Clause 6.2 above the Licensee shall be entitled for a period of one year from the date of termination to keep one copy of the Audit Tool in a fire-proof room for archival purposes only.

### 7 INDEMNITY

- 7.1 The Licensee shall indemnify and keep the Authority indemnified against any liability, costs, expenses, losses, claims or proceedings whatsoever arising under any statute or at common law or for breach of contract in respect of:
  - 7.1.1 damage to property, real or personal, including any infringement of third party Intellectual Property Rights;
  - 7.1.2 injury to persons, including injury resulting in death; and
  - 7.1.3 any Loss

arising out of, in connection with, or in respect of, any negligence, act, omission or default of the Licensee, its staff, agents or sub-contractors.

7.2 The Licensee shall be responsible for any acts, defaults, omissions, or neglect of any of its subcontractors or their agents or employees as if they were acts, defaults, omissions, or neglect of the Licensee.

### 8 CONFIDENTIALITY

- 8.1 Each of the parties hereto undertakes to the other to keep confidential all information (written or oral) concerning the business and affairs of the other that it shall have obtained or received as a result of the discussions leading up to or the entering into of this Agreement save that which:
  - 8.1.1 becomes public knowledge through no fault of the relevant party;
  - 8.1.2 was already in the relevant party's lawful possession and at its free disposal before the date of this Agreement;
  - 8.1.3 is lawfully disclosed to the relevant party without any obligations of confidence by a third party; or
  - 8.1.4 is required to be disclosed by a competent regulatory body, government body or body of competent jurisdiction.
- 8.2 Neither party will make any announcement relating to this Agreement or its subject matter without the prior written approval of the other party (such approval not to be unreasonably withheld or delayed).
- 8.3 Each of the parties undertakes to the other to take all such steps as shall from time to time be necessary to ensure compliance with the provisions of this Clause 7.2 by its employees, agents and sub-contractors.

### 9 THIRD PARTIES

9.1 No person who is not a party to this Agreement is intended to reserve a benefit under, or be entitled to enforce, this Agreement pursuant to the Contracts (Rights of Third Parties) Act 1999.

### 10 NOTICES

- 10.1 Any notice to be given under this Agreement shall be in writing, addressed to the Authority Representative or Licensee Representative (as appropriate) and either delivered personally, sent by facsimile or sent by first class recorded delivery post.
- 10.2 The address for service of the parties shall be:
  - 10.2.1 in the case of the Authority, the address referred to above in this Agreement or such other address as may from time to time be notified in writing to the Licensee;
  - 10.2.2 in the case of the Licensee, the address referred to above in this Agreement or its registered office or such other address as may from time to time be notified in writing to the Authority
- 10.3 The fax number for service of the parties shall be:
  - 10.3.1 in the case of the Authority, the Authority Fax Number;
  - 10.3.2 in the case of the Licensee, the Licensee Fax Number;
- 10.4 A notice shall be deemed to have been served:
  - 10.4.1 if personally delivered, at the time of delivery;
  - 10.4.2 if sent by facsimile, at 09.00 (local time) on the morning of the first business day of the recipient after faxing.;
  - 10.4.3 if posted, on the morning of the first business day of the recipient following the expiration of 48 hours after the envelope containing the same was delivered into the custody of the postal authorities.
- 10.5 A notice required to be given under this Agreement shall not be validly given if sent by email.

### 11 CHANGE OF DETAILS

- 11.1 The Authority may change the identity of the Authority Representative or the Authority Fax Number by notice in writing to the Licensee.
- 11.2 The Licensee may change the identity of the Licensee Representative or the Licensee Fax Number by notice in writing to the Authority.

### 12 GENERAL

- 12.1 The Licensee shall not be entitled to assign or otherwise transfer this Agreement nor any of its rights or obligations hereunder nor sub-license the use (in whole or in part) of the Audit Tool without the prior written consent of the Authority.
- 12.2 The waiver by either party of a breach or default of any of the provisions of this Agreement by the other party shall not be construed as a waiver of any succeeding breach of the same or other provisions nor shall any delay or omission on the part of either party to exercise or avail itself of any right power or privilege that it has or may have hereunder operate as a waiver of any breach or default by the other party.
- 12.3 No variation of this Agreement will be valid unless recorded in writing and signed by or on behalf of each of the parties to this Agreement.

- 12.4 If any provision of this Agreement (or part of any provision) is found by any court or other authority of competent jurisdiction or illegal, the other provisions will remain unaffected and in force.
- 12.5 Nothing in this Agreement will be construed as constituting or evidencing any partnership, contract of employment or joint venture of any kind between either of the parties or as authorising either party to act as agent for the other. Neither party will have authority to make representations for, act in the name or on behalf of or otherwise to bind the other party in any way.
- 12.6 Each party will, at the request of the other party and its own cost, do (or procure others to do) everything necessary to give the other party the full benefit of this Agreement.
- 12.7 This Agreement may be executed in any number of counterparts, each of which will be an original and all of which will together constitute a single agreement.
- 12.8 This Agreement constitutes the entire agreement and understanding between the parties in respect of the matters dealt with in and supersedes any previous agreement between the parties.
- 12.9 All conditions warranties terms and undertakings express or implied statutory or otherwise in respect of the Audit Tool are hereby excluded.
- 12.10 Each of the parties acknowledge and agrees that in entering into this Agreement it does not rely on, and will have no remedy in respect of, any statement, representation, warranty or understanding (whether negligently or innocently made) of any person (whether party to this Agreement or not) other than as expressly set out in this Agreement.
- 12.11 Neither the expiration nor the termination of this Agreement shall prejudice or affect any right action or remedy, which shall have accrued or shall thereafter accrue either to the Authority or to the Licensee.
- 12.12 The provisions of Clauses 6 (Intellectual Property), 7 (Termination), 8 (Indemnity), 9 (Confidentiality), 10 (Third Parties), 13 (General) and 14 (Governing Law and Jurisdiction) shall survive the termination or expiry of this Agreement.

#### 13 GOVERNING LAW AND JURISDICTION

- 13.1 This Agreement will be governed by and interpreted in accordance with the law of England and Wales.
- Each party irrevocably submits to the exclusive jurisdiction of the courts of England and Wales over any claim or matter arising under or in connection with this Agreement.



# National Audit of Schizophrenia (NAS) Audit of practice form

### Guidance notes for the second round of audit

Audit forms should be completed by the psychiatrist accountable for the patient's care If delegated, the psychiatrist accountable for the patient's care must confirm the data are correct.

### Please complete a separate audit form for each patient

Your audit lead will tell you which of your patients have been selected. Patients have been randomly selected from all patients in your Trust/ Health Board who meet the criteria for NAS. It is essential that you **do not make your own selection** of which patient to audit.

### How to complete this audit form

All data must be <u>collected</u> by **31 October 2013** and <u>submitted</u> online by **29 November 2013**. Please contact your local audit lead if you are unsure how this is being managed in your Trust/Health Board.

Audit forms should be completed using your knowledge of the patient. Please also refer to the paper and/or electronic patient records as you require.

For some questions, where information about physical health monitoring is not available from the patient's records, you or a member of your team may need to contact the patient's GP for this. A joint letter with our partner organisation, the Royal College of General Practitioners (RCGP), should have been provided along with this audit form for this purpose. This letter informs GPs about the audit and the reason for contacting them with any requests for data during data collection. An electronic version of this letter is available via your audit lead.

All questions marked \* are mandatory.

### Further assistance and information

Please contact your local audit lead in the first instance. You may also contact the central NAS Team on nas@cru.rcpsych.ac.uk or 020 7977 4980 / 6645 or visit our website at www.rcpsych.ac.uk/quality/NAS.

Your local audit lead is:	
The NAS ID for your organisation:	
Q1 NAS Patient ID* (To be completed by local audit lead)	
(Number 1-100 assigned by local audit lead for local tracking purposes)	
g purposes,	
Tick here when data are submitted online	
(For local monitoring purposes only)	

	A. Trust/Health Boa	ard and team
Q2	Initials of data collector/clinician*	
Q3	Clinical team responsible for the patient's	care* (Select one option only)
	Assertive Outreach Team	
	Community Mental Health Team	
	Crisis Resolution Team	
	Early Intervention in Psychosis Team	
	Other	
	B. Patient de	etails
Q4	Year of birth* (YYYY)	
Q5	Sex*	
	Male	
	Female	
	Indiscriminate	
Q6	Ethnicity *	<b>&gt;</b> .
	White	Chinese or other ethnic group
	Asian or Asian British	Mixed
	Black or Black British	Not stated
<b>Q7</b>	Current ICD-10 mental health diagnosis* (	Select one option only)
	F20 (Schizophrenia)	
	F25 (Schizoaffective Disorder)	
Q8	How long ago was this diagnosis first made (Patients whose diagnosis was less than 12 mor	
	Between 1-2 years	
	Up to 4 years	
	Up to 10 years	
	More than 10 years	

## C. Patient's current mental health

Q9	Please use your knowledge of the patient to rate patient's current mental health* (Select one option only in the appropriate column)  Please keep a note of your answer as this information will be needed later.			
	<ul><li>1 = Full remission</li><li>2 = Partial remission with minimal symptoms and</li></ul>	On clozapine	Not on clozapine	
	disability  3 = Partial remission with substantial symptoms and disability			
	4 = Not in remission			
	D. Antipsychotic medica	ation(s)		
Q10	Is this patient <u>currently</u> prescribed any antipsych  Yes  No			
I If the	patient is not currently prescribed any antipsychoti	cs go to 017		

## Q11 Please provide the current dose of all antipsychotics currently being prescribed for the patient

! The next two sections ask for information on names and doses of medications prescribed. Please record oral/depot/ Long Acting Injection (LAI) medications separately, in the appropriate sections. <u>Please note:</u> do not record information on doses of short acting Intramuscular (IM) injections as these are different from depots/LAI medications.

Oral Antipsychotics		
Amisulpride (oral) (mg/day)		
Aripiprazole (oral) (mg/day)		
Asenapine (oral) (mg/day)		
Benperidol (oral) (mg/day)	4	
Chlorpromazine (oral) (mg/day)		
Clozapine (oral) (mg/day)		
Flupentixol (oral) (mg/day)		
Fluphenazine (oral) (mg/day)		
Haloperidol (oral) (mg/day)		
Levomepromazine (oral) (mg/day)		
Olanzapine (oral) (mg/day)		
Paliperidone (oral) (mg/day)		
Pericyazine (oral) (mg/day)		
Perphenazine (oral) (mg/day)		
Pimozide (oral) (mg/day)		
Promazine (oral) (mg/day)		
Quetiapine (oral) (mg/day)		
Risperidone (oral) (mg/day)		
Sertindole (oral) (mg/day)		
Sulpiride (oral) (mg/day)		
Trifluoperazine (oral) (mg/day)		
Zotepine (oral) (mg/day)		
Zuclopenthixol (oral) (mg/day)		
OTHER ORAL antipsychotic (name and dose) (mg/day)		

Fluphenazine would be entered as 150mg of Fluphenazine per week Depot/ long-acting Intra-muscular antipsychotics Aripiprazole (long-acting) (mg/week) Flupentixol (depot) (mg/week) Fluphenazine (depot) (mg/week) Haloperidol (depot) (mg/week) Olanzapine (long-acting) (mg/week) Paliperidone (long-acting) (mg/week) Risperidone (long-acting) (mg/week) Zuclopenthixol (depot) (mg/week) OTHER DEPOT or LAI antipsychotic (name and dose) (mg/week) If the current antipsychotic dose is known to be above the BNF recommended Q12 dose, has a rationale for this been documented in the patient's records? Yes..... No..... Do not know ..... ..... N/A, no doses above BNF recommended dose..... If the patient is currently being prescribed two or more antipsychotic drugs at the Q13 same time, has a rationale for this been documented in the patient's records? Yes..... No ..... Do not know ..... N/A, currently prescribed only one antipsychotic medication ...... ! Only answer Q14-16 if the patient is currently prescribed clozapine. Q14 How long has the patient been on clozapine? 3 months or less ..... Between 3 to 12 months..... More than 12 months.....

! Please enter all depot/long-acting doses as weekly doses e.g. a fortnightly 300mg dose of

Q15	What was the reason for starting the patient on clozapine?
	Treatment resistant/ poor response
	Adverse effects of previous antipsychotic medication
	Both of the above
	Not known
	Other
	If 'OTHER' please state
Q16	How many antipsychotic medications was the patient prescribed before clozapine?
	None
	One
	Two
	Three or more
Q17	Was the patient provided with written information (or an appropriate alternative) about the most recent antipsychotic prescribed?* (Select one option only)
	Yes
	No
	Do not know
	N/A, patient never prescribed an antipsychotic
Q18	Were the benefits and side effects of the <u>most recent</u> antipsychotic medication prescribed, discussed with the patient?* (Select one option only)
	Yes
	No
	Do not know
	N/A, patient never prescribed an antipsychotic
Q19	For the most recently prescribed antipsychotic, was the patient involved in deciding which antipsychotic they were prescribed?* (Select one option only)
	Yes
	No
	Do not know
	N/A, patient never prescribed an antipsychotic

- ! Only answer Q20-25 (Section E) if:
- The patient has current significant symptoms and disability (Q9 rated 3 or 4) and
- is not currently prescribed clozapine

# E. History of prescribing for patients <u>not</u> in remission and <u>not</u> currently prescribed clozapine

Q20	Why is this patient not currently prescribed clozapine? (Tick as many as applicable)  Not yet had adequate trial of two other antipsychotics
	None of Above please state reason
Q21	Is the current antipsychotic the first antipsychotic medication prescribed for the patient?  Yes
	No.
Q22	How many other antipsychotics did the patient receive before the current one?
	None
	One
	Two
	Three or more
Q23	How long has the patient been on the current antipsychotic medication?
	8 weeks or less
	Between 8 weeks to 6 months
	More than 6 months
Q24	In the past 12 months, has medication adherence been investigated as a potential cause of inadequate response to antipsychotic medications?
	Yes
	No
Q25	In the past 12 months, has alcohol or substance misuse been investigated as a potential cause of inadequate response to antipsychotic medications?
	Yes
	No

! Do not answer Q26-29 (Section F) if you have answered Q20-25 (Section E).

! Only answer Q26-29 (Section F) if:

- The patient has current significant symptoms and disability (Q9 rated 3 or 4) and
- is currently prescribed clozapine

# F. History of prescribing for patients <u>not</u> in remission and <u>currently</u> being prescribed clozapine

Q26	Before starting clozapine was the patient trialled on at least one second- generation antipsychotic?		
	Yes		
	No		
Q27	If the patient is currently prescribed clozapine <u>plus</u> another antipsychotic, has the patient been trialled on this combination for at least 8 weeks at optimal dose?		
	Yes		
	No		
	Currently only prescribed clozapine with no other antipsychotics		
Optimal o	dose: up to 3/4 of BNF maximum dose or until side effects preclude further dose increase.		
Q28	In the past 12 months, has medication adherence been investigated as a potential cause of inadequate response to antipsychotic medications?		
	Yes		
	No		
Q29	In the past 12 months, has alcohol or substance misuse been investigated as a potential cause of inadequate response to antipsychotic medications?		
	Yes		
	No		

## G. Physical Health Monitoring

! For Q30-40 we would like to know what physical health monitoring has been undertaken by you or the patient's GP, selecting patients in the 12 months leading up to the census date of <u>1 July 2013</u>. If your records do not contain the necessary information about physical health please contact the patient's GP.

aitii	picase contact ti	io patient 3 c	•			
Q30	•			e following sigi record or the C	P's records)?*	
			D'a sur a sa d	December	No record	
		Recorded	Diagnosed but not	Recorded as no problem	but known not to have	
		diagnosis	recorded	present	problem	Not known
	Cardiovascular Disease					
	Diabetes					
	Hypertension					
	Dyslipidaemia					
					77	
		H. Phys	sical Heal	th Record	S	
or fron inform	e note: For Q31-4 n the GP. <u>Only</u> ind ation since learni	clude results ing that this	from the past patient had be	12 months. If y en selected for	ou have obtair the audit, plea	ied this se <u>do</u> report
the res	sults here. <u>If ther</u>	e is no record	<u>u or a measure</u>	being taken, p	iease leave the	BOX BIANK.
Q31	Smoking statu	IS				
	Current sm	oker (includes	patients who qu	uit smoking <12	months ago)	
	Non smoke	r (includes pat	ients who quit s	moking >12 mor	nths ago)	
Q32	Current alcoho (Number of unit					
Q33	Current substa	ance misuse?				
	Yes					
	No					
	ne following ques e is no record of					ot 90cm
Q34	Current/most (kg/m²)	recent BMI	(Body Mass In	dex)		
Q35	Waist circumfe	erence (cm)				
Q36	Current/most	recent blood	pressure			
	Systolic (m					
	Diastolic (r	mmHg)				

### Q37 Current/most recent glucose Fasting plasma glucose (mmol/l) and/or Glycated haemoglobin (mmol/mol) Q38 **Current/most recent cholesterol** Total cholesterol (mmol/l) High density lipoprotein (HDL) cholesterol (mmol/l) Q39 Family history (1st degree relatives only) of: Yes No record Cardiovascular disease (first diagnosed under 60 yrs) Diabetes Hypertension Dyslipidaemia Q40 Has an intervention been offered, or a referral been made, within the past 12 months for any of the following: Yes No Advice about diet and exercise Treatment for cardiovascular disease Treatment for diabetes Treatment for dyslipidaemia Treatment for hypertension Help with smoking cessation Help with reducing alcohol consumption Help with reducing substance misuse What was the source of the information used to answer Questions 31-42? Q41 (Select one option only) Case record and psychiatrist knowledge only ..... Case record, psychiatrist knowledge plus GP ...... GP only ..... Other..... If 'OTHER' please state

! For Q37, if glycated haemoglobin is not available as mmol/mol, please visit the NAS

website www.rcpsych.ac.uk/quality/nas/round2methods.

### I. Psychological Therapies Has Cognitive Behavioural Therapy (CBT) ever been offered to the patient? \* Q42 Yes..... No, but was available ..... No, as CBT was **not** available..... Q43 Has family intervention (where patient is in contact with the family) ever been offered to the patient?\* Yes..... No, but was available ..... No, as family intervention was **not** available..... If psychological therapy offered, was this taken up by the patient? Q44 Family **CBT** intervention Yes, was taken up Not taken up - patient refused Not taken up - reason not recorded Do not know Other If 'OTHER' please state

J.	Care	pla	an

Q45	Does the patient have a current care plan*?
	Yes
	No
	Do not know

### Online Data Entry

Data must now be entered online at <a href="https://www.rcpsych.ac.uk/quality/nasround2/audittool">www.rcpsych.ac.uk/quality/nasround2/audittool</a>. The Central NAS Team cannot accept data from Trusts via post, fax or email.

Please contact your local audit lead, whose details are on the front of this form, if you are unsure how this is being managed in your Trust/Health Board.

The latest date for <u>collection</u> of data is **31 October 2013**. The latest date for <u>online submission</u> of data is **29 November 2013**.

It will not be possible to submit data after this date and extensions will not be given. Medical directors and audit leads will be provided with ongoing updates on the number of audit forms being submitted online.

Thank you for completing this audit form for your patient.

### **End of Audit Form**